Lyell Immunopharma’s LYL845 Receives the US FDA’s Orphan Drug Designation to Treat Melanoma
Shots:
- The ODD was granted to LYL845 which is being evaluated in a P-I clinical trial in patients with r/r metastatic or locally advanced melanoma, NSCLC & CRR. The 1EPs of the study incl. safety, tolerability & RP2D whereas the 2EPs incl. response rate, DoR, PFS & OS
- Previous non-clinical studies of LYL845 have depicted characteristics associated with improved CR rate incl. higher percentage of cytotoxic T cells and stemness phenotypes along with an enhanced T-cell potency & maintenance of tumor-reactive polyclonality
- LYL845 is an autologous TIL product that is enhanced by Lyell’s Epi-RTM manufacturing techniques that develop polyclonal populations of T cells depicting properties of durable stemness & anti-tumor functionality
Ref: Lyell Immunopharma | Image: Lyell Immunopharma
Related News:- GSK Signs a Five Years Collaboration with Lyell to Develop Technologies Improving Cell Therapies for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
